JS016, a new COVID-19 treatment with China's independent intellectual property, has been approved for emergency use by 15 countries, with the combination of another neutralizing antibody, CCTV News reported on Friday morning.
Currently, Phase 3 clinical trials of the neutralizing antibody medicine are being promoted actively in the country, according to the Chinese Academy of Sciences' Institute of Microbiology.
Its safety and efficacy in treating COVID-19 patients has been recognized, providing a new approach for the prevention and control of COVID-19 globally.
Go to Forum >>0 Comment(s)